Author

Thao T. Tang

Observed names: Thao T Tang, Thao Tang

Observed institutions: University of Washington, Fred Hutch Cancer Center

ORCID: 0009-0008-9456-1699

Observed ORCID: 0009-0008-9456-1699

OpenAlex ID: A5030930120

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

2022 · Quy Le, Brandon Hadland, et al. · Journal of Clinical Investigation · 54

PDF

Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia

2022 · Danielle C. Kirkey, Anisha M. Loeb, et al. · Blood Advances · 40

PDF

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia

2021 · Allison J. Kaeding, Sonali P. Barwe, et al. · Blood Advances · 37

PDF

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia

2021 · Quy Le, Sommer Castro, et al. · Clinical Cancer Research · 31

PDF

Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate

2022 · Thao Tang, Quy Le, et al. · Blood Advances · 23

Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia

2023 · Quy Le, Thao Tang, et al. · Blood Advances · 20

PDF

Defining the impact of mutation accumulation on replicative lifespan in yeast using cancer-associated mutator phenotypes

2019 · Mitchell B. Lee, Ian T. Dowsett, et al. · Proceedings of the National Academy of Sciences · 20

PDF

Spontaneous Polyploids and Antimutators Compete During the Evolution of Saccharomyces cerevisiae Mutator Cells

2020 · Maxwell A. Tracy, Mitchell B. Lee, et al. · Genetics · 11

PDF

Pterocarpus marsupium extract extends replicative lifespan in budding yeast

2021 · Mitchell B. Lee, Michael G. Kiflezghi, et al. · GeroScience · 9

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

2024 · Quy Le, Brandon Hadland, et al. · Journal of Clinical Investigation · 7

PDF

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor Natural Killer Cell Therapy in Acute Myeloid Leukemia

2021 · Thao T. Tang, Lindsey F Call, et al. · Blood · 4

Abstract 1075: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C’Dot-drug-conjugate

2022 · Quy Le, Feng Chen, et al. · Cancer Research · 3

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

2021 · Quy Le, Jenny L. Smith, et al. · Blood · 3

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

2021 · Quy Le, Amanda R. Leonti, et al. · Blood · 3

Targeting PRAME with TCR-Mimic CAR T Cells in AML

2021 · Anisha M Loeb, Sommer Castro, et al. · Blood · 3

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

2020 · Katherine Tarlock, Todd A. Alonzo, et al. · Blood · 3

IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy

2025 · Shayan C. Avanessian, Renske J.E. van den Bijgaart, et al. · Cancer Immunology Research · 1

Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.

2023 · Danielle Kirkey, Leila Robinson, et al. · Journal of Clinical Oncology · 1

CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformation

2021 · Quy Le, Brandon Hadland, et al. · Research Square · 1

PDF

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

2020 · Quy Le, Sommer Castro, et al. · Blood · 1

Figure S2 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy